# Perceived disabling physical pain and suicidal ideation in aging people living with HIV cured of hepatitis C: A multi-center survey in France (ANRS CO13 HEPAVIH)

Tangui Barré, Clémence Ramier, Camelia Protopopescu, Philippe Sogni, Karine Ory, Tounes Saidi, Sophie Abgrall, Sylvie Brégigeon-ronot, Patrizia Carrieri, Fabienne Marcellin

► To cite this version:

Tangui Barré, Clémence Ramier, Camelia Protopopescu, Philippe Sogni, Karine Ory, et al. Perceived disabling physical pain and suicidal ideation in aging people living with HIV cured of hepatitis C: A multi-center survey in France (ANRS CO13 HEPAVIH). HIV Medicine, 2025, 10.1111/hiv.70121. hal-05413901

HAL Id: hal-05413901

https://hal.science/hal-05413901v1

Submitted on 16 Dec 2025

HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire HAL, est
destinée au dépôt et à la diffusion de documents
scientifiques de niveau recherche, publiés ou non,
émanant des établissements d'enseignement et de
recherche français ou étrangers, des laboratoires
publics ou privés.

<figure><img src="image_1.png" /></figure>
ORIGINAL ARTICLE

# Perceived disabling physical pain and suicidal ideation in aging people living with HIV cured of hepatitis C: A multi-center survey in France (ANRS CO13 HEPAVIH)

Tangui Barré<fnref n="1" /> ID | Clémence Ramier<fnref n="1" /> ID | Camelia Protopopescu<fnref n="1" /> ID |
Philippe Sogni<fnref n="2" />,<fnref n="3" />,<fnref n="4" /> ID | Karine Ory<fnref n="5" /> | Tounes Saidi<fnref n="6" /> | Sophie Abgrall<fnref n="7" />,<fnref n="8" /> ID |
Sylvie Brégigeon-Ronot<fnref n="9" /> ID | Patrizia Carrieri<fnref n="1" /> ID | Fabienne Marcellin<fnref n="1" /> ID |
the ANRS CO13 HEPAVIH Study Group*

**Correspondence**

Camelia Protopopescu, Aix Marseille Univ., Inserm, IRD, SESSTIM, Sciences Economiques and Sociales de la Santé and Traitement de l'Information Médicale, ISSPAM, Marseille, France.

Email: camelia.protopopescu@inserm.fr

**Funding information**

ANRS Emerging Infectious Diseases (ANRS MIE); Sidaction; Abbott France; GlaxoSmithKline; Roche; Schering-Plough; Bristol-Myers Squibb; Merck-Serono

**Abstract**

**Introduction:** Suicidal ideation (SI) is highly prevalent among people living with HIV (PWH) and those with chronic hepatitis C virus (HCV) infection. Individuals with long-term HIV-HCV co-infection face specific health challenges, including heightened physical pain. We aimed to assess whether disabling physical pain is associated with SI in aging PWH who have been cured of HCV, after controlling for potential correlates or confounders such as depression and psychoactive substance use.

**Methods:** We analysed data from HCV-cured PWH who participated in a multi-center cross-sectional survey embedded within the French ANRS CO13 HEPAVIH cohort. We performed a multivariable logistic regression model with SI (score >0 for the ninth item of the Patient Health Questionnaire-9) as the outcome. Disabling physical pain was assessed using an answer ≥'very much' to the third item from the WHOQOL-HIV BREF questionnaire.

<footnote n="1">¹Aix Marseille Univ, Inserm, IRD, SESSTIM, Sciences Economiques & Sociales de la Santé & Traitement de l'Information Médicale, ISSPAM, Marseille, France</footnote>

<footnote n="2">²Université Paris Descartes, Paris, France</footnote>

<footnote n="3">³INSERM U1223, Institut Pasteur, Paris, France</footnote>

<footnote n="4">⁴Service d'Hépatologie, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Paris, France</footnote>

<footnote n="5">⁵Université Bordeaux, INSERM, MART, UMS 54, Bordeaux, France</footnote>

<footnote n="6">⁶Department of Clinical Research, ANRS Emerging Infectious Diseases (ANRS MIE), Paris, France</footnote>

<footnote n="7">⁷Assistance Publique-Hôpitaux de Paris (APHP), Hôpital Béclère, Service de Médecine Interne, Clamart, France</footnote>

<footnote n="8">⁸APHP, Université Paris-Saclay, Université Paris-Sud, UVSQ, CESP INSERM U1018, Le Kremlin-Bicêtre, France</footnote>

<footnote n="9">⁹Clinical Immunohematology Department, Marseille Public University Hospital System (AP-HM), Sainte-Marguerite Hospital, Aix-Marseille University, Marseille, France</footnote>

<footnote>*Members of the ANRS CO13 HEPAVIH Study Group are given in Acknowledgements.</footnote>

<footnote>This is an open access article under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</footnote>

<footnote>© 2025 The Author(s). *HIV Medicine* published by John Wiley & Sons Ltd on behalf of British HIV Association.</footnote>
**Results:** Study population comprised 396 HCV-cured PWH (73.2% male), among whom 17.7% reported SI and 11.9% reported disabling physical pain. Participants reporting disabling physical pain had a three-fold higher risk of SI (adjusted odds ratio [95% confidence interval]: 3.07 [1.29–7.34]), after adjustment for depression (5.52 [2.66–11.43]), substance use, and lower social relationships-related quality of life (0.72 [0.64–0.80]).

**Conclusions:** These findings highlight that disabling physical pain should be systematically addressed among PWH cured of HCV, given its independent association with SI. Routine HIV follow-up care should integrate systematic screening for pain, mental health problems, and lack of social support. Timely referral to specialized services may help prevent future suicidal behaviours in this population.

### KEYWORDS

depression, HCV cure, HIV-HCV co-infection, self-reports, suicide risk

## INTRODUCTION

Mental health problems are highly prevalent among people living with HIV (PWH), particularly depression [1, 2], and psychoactive substance (thereafter ‘substance’) use disorders [3–6]. In the first 2 years after diagnosis, PWH are at particularly high risk of depression and suicide [7]. Likewise, people with a longer history of HIV infection can also bear a high burden of depression, potentially related to the number of comorbidities they experience [8, 9]. Of particular concern, PWH exhibit higher rates of suicidal ideation (SI) and suicide than the general population [10–13]. It is noteworthy that SI is highly prevalent in sub-groups of people overrepresented in the PWH population, namely people who inject drugs and men who have sex with men [14, 15]. As a predictor of both attempted and completed suicide, SI represents a major health concern, linked to mental disorders, such as depression and anxiety [16]. It is also associated with social health determinants such as living alone or being unmarried [17–19], being the subject of gossip [18], poor family or social support [16, 20–22], and perceived stigma [21, 23, 24]. Moreover, SI has been associated with both lower adherence to anti-retroviral therapy and higher HIV viral loads [17, 20, 25, 26]. Identifying factors associated with SI in PWH is therefore essential for improving screening and implementing timely interventions to prevent suicide attempts and optimize HIV care.

Pain is among the most frequently reported symptoms in PWH [27], with older age being a primary risk factor [28]. Given its impact on multiple dimensions of quality of life [29], PWH consistently identify pain as a key health priority [30]. Pain is associated with substance use and depression, as well as with a reduced adherence to antiretroviral therapy [31, 32]. However, few studies

have examined the association between pain and SI in PWH. Although two studies have reported pain to be associated with suicidality or SI [33, 34], they did not simultaneously adjust for substance use, depression, and social factors. From a small sample of PWH from Alabama, Dafoe & Stewart reported a positive association between pain severity (using a continuous measure) and suicidality (including ideation, intent, and plan). They did not adjust their analyses for depression but included a reported ‘number of psychiatric diagnoses’ that indifferently summed up the presence of anxiety, mood, and substance use disorders [34]. In Rukundo et al.’s study from PWH in Uganda, the association found between physical pain (presence/absence) and SI or attempts was no longer significant after multivariable adjustment, including a recent HIV diagnosis [33]. Given the interrelated nature of these factors [35–37], there is a need to understand their respective contributions to SI.

Hepatitis C is known to be associated with a high prevalence of both depression [38] and substance use [39, 40]. Hepatitis C co-infection has been associated with suicide risk in PWH [41]. Hepatitis C cure is likely to reduce depressive symptoms [42], including among people who inject drugs [43], and those co-infected with HIV [44], and has been associated with improvements in both health-related quality of life and symptoms [45–47]. However, individuals cured of hepatitis C do not always report meaningful pain reduction [48, 49], and depressive symptoms may remain common among PWH following hepatitis C cure [50]. Post-cure pain persistence is not fully understood. It may be related to unresolved HCV-related neuropathic pain [51] or result from the impact of confounding factors such as psychiatric comorbidities [48]. PWH cured of hepatitis C may therefore be at particularly high risk of SI.
This study aimed to assess the relationship between self-reported disabling physical pain and SI in aging HCV-cured PWH, with a long-standing history of hepatitis C virus (HCV) co-infection, while accounting for other correlates or confounders such as depression and substance use.

# MATERIALS AND METHODS

## Design

We used data from a multi-center cross-sectional survey conducted between February 2018 and May 2019, and nested within the ANRS CO13 HEPAVIH French prospective cohort of adult (age ≥ 18 years) people living with HIV and HCV [50]. This survey aimed to assess changes in socio-behavioural patient-reported outcomes following HCV cure [52]. All participants enrolled in the cohort provided written informed consent. The ANRS CO13 HEPAVIH cohort was designed and conducted in accordance with the Declaration of Helsinki and received approval from the ethics committee of Cochin University Hospital in Paris. All cohort participants were invited to take part in the cross-sectional survey.

## Data collection

Survey participants were invited to complete a paper self-administered questionnaire collecting sociodemographic, behavioural, and perceived health-related data. Among behavioural data, tobacco use was assessed with the following question: ‘Currently, are you a smoker?’ (No, and I never smoked; No, but I smoked in the past; Yes). Cannabis use over the past 12 months was also recorded (No; Less than once a month; One to three times a month; One to six times a week; Every day). Alcohol use was assessed using the AUDIT-C screening tool [53]. Use of cocaine, crack, amphetamines, heroin, street buprenorphine, cathinones, ecstasy, and LSD or other hallucinogens in the past 4 weeks was collected (Never; Sometimes; Regularly; Daily). Regarding perceived health, participants completed the Patient Health Questionnaire-9 (PHQ-9) [54], a nine-item symptom checklist suitable for use in routine HIV care to evaluate the presence and severity of depressive symptoms [55]. In addition, participants were asked whether they were currently taking a treatment against depression prescribed by a physician. Participants also completed the WHOQOL-HIV BREF questionnaire, a 31-item instrument developed to assess quality of life among PWH [56]. Biomedical characteristics were obtained from clinical data

collected during the follow-up visit closest to the date of questionnaire completion.

## Study population

From participants who completed the survey, we selected people who reported being cured of hepatitis C and with available data for SI. No age-based criterion was further applied.

## Assessment of suicidal ideation

SI was assessed using the ninth item of the PHQ-9: ‘Over the last 2 weeks, how often have you been bothered by thoughts that you would be better off dead or of hurting yourself in some way?’ with possible answers scored as 0 (never), 1 (several days), 2 (more than half the days), and 3 (nearly every day). Based on previous studies [57, 58], a score >0 was indicative of SI.

## Assessment of perceived disabling physical pain

Participants were asked the following question: ‘To what extent do you feel that physical pain prevents you from doing what you need to do?’ (not at all; a little; a moderate amount; very much; an extreme amount) [56]. Participants who answered ‘very much’ or ‘an extreme amount’ were considered to be reporting disabling physical pain. Participants therefore reported the impact of pain on their daily functioning, but not the type of pain they experienced.

## Other potential correlates of suicidal ideation

Socio-demographic characteristics examined for their association with SI included sex, age, place of birth (France vs. abroad), and living in a couple (yes; no). Being born abroad is associated with a lower standard of living in France [59], and it may be associated with poorer health status and detrimental health events [60–62], including mental health issues such as depression [63]. Living in a couple is likely to enhance social support and prevent from the occurrence of depression [64], and being unmarried has been associated with SI in PWH [17].

Depression was defined as either being prescribed an anti-depressant treatment or, in cases of missing anti-
depressant treatment data, having a PHQ-9 score ≥ 10. The social relationships dimension of quality of life was assessed using the corresponding domain of the WHOQOL-HIV BREF questionnaire. This domain comprises four items, yielding a score ranging from 4 to 20, with higher scores indicating better social relationships. If only one of the four items was missing, its value was imputed using the mean of the remaining three items.

We used a substance use variable designed based on the approach used by Satre et al. [57]. Seven substances or substance groups were included: tobacco, cannabis, alcohol, stimulants (cocaine, crack, amphetamines), opioids (heroin, street buprenorphine), empathogens (cathinones, ecstasy), and LSD or other hallucinogens. For each of these, a binary score (0 or 1) was assigned to participants as follows: for tobacco use, in case of current use; for cannabis use, in case of a daily use; for alcohol use, in case of an AUDIT-C score ≥3 for women and ≥4 for men; and for other substances, in case of any use in the past 4 weeks. The seven binary scores obtained were then summed to obtain a global substance use score.

The different approaches to score tobacco, cannabis, and alcohol use (based on a frequency of use) and other substance use (based on any use in the past 4 weeks) relied on the following considerations: (i) because the use of other substances is less common, frequency data were not collected, as statistical power would have been insufficient to account for it; (ii) published literature suggests dose-response relationships between the use of tobacco [65], cannabis [66], alcohol [67], and suicidal behaviours.

Biomedical characteristics included self-reported HIV transmission mode (male-to-male sex; heterosexual sex; injecting drug use; other/unknown), HIV viral load (undetectable; detectable; no lab results), time since HIV and time since HCV diagnosis (in years), CD4 cell count (>500; 351–500; 200–350; <200, in cells/mm³), and history of treatment with efavirenz or interferon.

## Statistical analyses

Characteristics of the study population were described and compared according to the presence of SI, using the Chi-squared test or Fisher exact test for categorical variables and the Kruskal-Wallis test for continuous variables.

The association between perceived disabling physical pain and SI was explored using multivariable logistic regression. Explanatory variables were first tested in univariable analyses. Those with a p-value <0.2 were eligible

for the multivariable analysis [68]. A backward stepwise selection procedure was used to select variables for the final multivariable model, with a p-value threshold of 0.05. Variables eligible for multivariable analyses which were eliminated during the backward stepwise selection procedure were then reintroduced to test for potential changes in the significance level of associations and/or changes in the adjusted odds ratio (aOR) estimates of variables in the final model. If the aOR for at least one of the remaining variables changed by more than 25%, the eliminated variable was deemed to be a confounder and restored to the model [69]. A robust sandwich estimator was used to estimate the variance of the odds ratios. All analyses were performed with Stata software version 17.0 for Windows (StataCorp LP, College Station, TX).

## RESULTS

### Study population characteristics

Characteristics of the 396 participants in the study population are presented in Table 1. The majority were male (73.2%), and the median [interquartile range, IQR] age was 55.5 [53–59] years. The median [IQR] time since HIV diagnosis was 29.0 [23.3–31.8] years, and the median [IQR] time since HCV diagnosis was 21.2 [16.9–25.0] years. Sixty-one percent of participants acquired HIV via injection drug use (21.0% of them reported SI). SI was reported by 70 participants (17.7%). Approximately one-third of participants (32.1%) reported using one substance; among them, 74.0% smoked tobacco and 25.6% had unhealthy alcohol use. Another third (34.3%) reported using at least two substances, with the vast majority being tobacco smokers (94.2% of those using two substances and 93.9% of those using three or more). Perceived disabling physical pain was reported by 46 participants (11.9%), including 18 who also reported SI (Table 1). Among participants with SI, 48.6% reported using at least two substances, 44.3% had depression, and 17.1% had a detectable HIV viral load.

### Perceived disabling physical pain and suicidal ideation: a multivariable analysis

After multivariable adjustment, participants reporting disabling physical pain had a three-fold higher risk of SI (aOR [95% confidence interval]: 3.07 [1.29–7.34], *p* = 0.012) (Table 2). Moreover, the use of at least two substances (2.78 [1.07–7.26] and 5.42 [1.73–16.93], for two substances and three or more substances, respectively), depression (5.52 [2.66–11.43]), and a lower quality
<table><caption>TABLE 1 Study population characteristics according to suicidal ideation (cross-sectional survey nested within the ANRS CO13 HEPAVIH cohort, N = 396).</caption><thead><tr><th>Characteristics<br>(% of missing data)</th><th>Study population (N = 396)<br>N (%) or median [IQR]</th><th>No suicidal<br>ideation (N = 326)<br>N (%) or median [IQR]</th><th>Suicidal ideation (N = 70)<br>N (%) or median [IQR]</th><th>p-Value<sup>a</sup></th></tr></thead><tbody><tr><td>Perceived disabling<br>physical pain<sup>b</sup> (2.0)</td><td></td><td></td><td></td><td>&lt;0.001</td></tr><tr><td>No</td><td>342 (88.1)</td><td>292 (91.3)</td><td>50 (73.5)</td><td></td></tr><tr><td>Yes</td><td>46 (11.9)</td><td>28 (8.7)</td><td>18 (26.5)</td><td></td></tr><tr><td>Sex (0)</td><td></td><td></td><td></td><td>0.205</td></tr><tr><td>Male</td><td>290 (73.2)</td><td>243 (74.5)</td><td>47 (67.1)</td><td></td></tr><tr><td>Female</td><td>106 (26.8)</td><td>83 (25.5)</td><td>23 (32.9)</td><td></td></tr><tr><td>Age (in years) (0)</td><td>55.5 [53–59]</td><td>55.5 [53–59]</td><td>55.5 [52–59]</td><td>0.740</td></tr><tr><td>Place of birth (0)</td><td></td><td></td><td></td><td>0.389</td></tr><tr><td>France</td><td>307 (77.5)</td><td>250 (76.7)</td><td>57 (81.4)</td><td></td></tr><tr><td>Abroad</td><td>89 (22.5)</td><td>76 (23.3)</td><td>13 (18.6)</td><td></td></tr><tr><td>Living in a couple (1.0)</td><td></td><td></td><td></td><td>0.090</td></tr><tr><td>No</td><td>208 (53.1)</td><td>165 (51.1)</td><td>43 (62.3)</td><td></td></tr><tr><td>Yes</td><td>184 (46.9)</td><td>158 (48.9)</td><td>26 (37.7)</td><td></td></tr><tr><td>HIV transmission mode (0)</td><td></td><td></td><td></td><td>0.121</td></tr><tr><td>Male-to-male sex</td><td>44 (11.1)</td><td>37 (11.3)</td><td>7 (10.0)</td><td></td></tr><tr><td>Heterosexual sex</td><td>59 (14.9)</td><td>54 (16.6)</td><td>5 (7.1)</td><td></td></tr><tr><td>Injecting drug use</td><td>243 (61.4)</td><td>192 (58.9)</td><td>51 (72.9)</td><td></td></tr><tr><td>Other/unknown</td><td>50 (12.6)</td><td>43 (13.2)</td><td>7 (10.0)</td><td></td></tr><tr><td>HIV viral load<sup>c</sup> (0)</td><td></td><td></td><td></td><td>0.049</td></tr><tr><td>Undetectable</td><td>326 (82.3)</td><td>275 (84.4)</td><td>51 (72.9)</td><td></td></tr><tr><td>Detectable</td><td>39 (9.8)</td><td>27 (8.3)</td><td>12 (17.1)</td><td></td></tr><tr><td>No lab results</td><td>31 (7.8)</td><td>24 (7.4)</td><td>7 (10.0)</td><td></td></tr><tr><td>Time since HIV diagnosis<br>(in years) (0.3)</td><td>29.0 [23.3–31.8]</td><td>29.1 [23.3–31.9]</td><td>28.6 [23.4–31.3]</td><td>0.545</td></tr><tr><td>Time since HCV diagnosis<br>(in years) (3.5)</td><td>21.2 [16.9–25.0]</td><td>21.1 [16.8–34.8]</td><td>22.0 [17.0–25.8]</td><td>0.375</td></tr><tr><td>CD4 cell count (in cells/mL) (0)</td><td></td><td></td><td></td><td>0.177</td></tr><tr><td>&gt;500</td><td>242 (61.1)</td><td>204 (62.6)</td><td>38 (54.3)</td><td></td></tr><tr><td>351–500</td><td>59 (14.9)</td><td>42 (12.9)</td><td>17 (24.3)</td><td></td></tr><tr><td>200–350</td><td>38 (9.6)</td><td>31 (9.5)</td><td>7 (10.0)</td><td></td></tr><tr><td>&lt;200</td><td>16 (4.0)</td><td>13 (4.0)</td><td>3 (4.3)</td><td></td></tr><tr><td>No lab results</td><td>41 (10.4)</td><td>36 (11.0)</td><td>5 (7.1)</td><td></td></tr><tr><td>History of interferon treatment (2.8)</td><td></td><td></td><td></td><td>0.146</td></tr><tr><td>No</td><td>117 (30.4)</td><td>92 (28.8)</td><td>25 (37.9)</td><td></td></tr><tr><td>Yes</td><td>268 (69.6)</td><td>227 (71.2)</td><td>41 (62.1)</td><td></td></tr><tr><td>History of efavirenz treatment (2.8)</td><td></td><td></td><td></td><td>0.174</td></tr><tr><td>No</td><td>210 (54.5)</td><td>169 (53.0)</td><td>41 (62.1)</td><td></td></tr><tr><td>Yes</td><td>175 (45.5)</td><td>150 (47.0)</td><td>25 (37.9)</td><td></td></tr><tr><td>Number of psychoactive substances used<sup>d</sup> (0)</td><td></td><td></td><td></td><td>0.007</td></tr><tr><td>0</td><td>133 (33.6)</td><td>121 (37.1)</td><td>12 (17.1)</td><td></td></tr></tbody><tfoot><tr><td colspan="5" style="text-align: right;">(Continues)</td></tr></tfoot></table>
<table><caption>TABLE 1 (Continued)</caption><thead><tr><th>Characteristics<br>(% of missing data)</th><th>Study population (N = 396)<br>N (%) or median [IQR]</th><th>No suicidal<br>ideation (N = 326)<br>N (%) or median [IQR]</th><th>Suicidal ideation (N = 70)<br>N (%) or median [IQR]</th><th>p-Value<sup>a</sup></th></tr></thead><tbody><tr><td>1</td><td>127 (32.1)</td><td>103 (31.6)</td><td>24 (34.3)</td><td></td></tr><tr><td>2</td><td>103 (26.0)</td><td>78 (23.9)</td><td>25 (35.7)</td><td></td></tr><tr><td>≥3</td><td>33 (8.3)</td><td>24 (7.4)</td><td>9 (12.9)</td><td></td></tr><tr><td>Current tobacco use (0)</td><td></td><td></td><td></td><td>0.010</td></tr><tr><td>No</td><td>174 (43.9)</td><td>153 (46.9)</td><td>21 (30.0)</td><td></td></tr><tr><td>Yes</td><td>222 (56.1)</td><td>173 (53.1)</td><td>49 (70.0)</td><td></td></tr><tr><td>Unhealthy alcohol use<sup>e</sup> (1.3)</td><td></td><td></td><td></td><td>0.065</td></tr><tr><td>No</td><td>255 (65.2)</td><td>216 (67.3)</td><td>39 (55.7)</td><td></td></tr><tr><td>Yes</td><td>136 (34.8)</td><td>105 (32.7)</td><td>31 (44.3)</td><td></td></tr><tr><td>Daily cannabis use (1.8)</td><td></td><td></td><td></td><td>0.128</td></tr><tr><td>No</td><td>343 (88.2)</td><td>385 (89.3)</td><td>58 (82.9)</td><td></td></tr><tr><td>Yes</td><td>46 (11.8)</td><td>34 (10.7)</td><td>12 (17.1)</td><td></td></tr><tr><td>Use of other psychoactive substances<sup>f</sup> (6.6)</td><td></td><td></td><td></td><td>0.226</td></tr><tr><td>No</td><td>344 (93.0)</td><td>284 (93.7)</td><td>60 (89.5)</td><td></td></tr><tr><td>Yes</td><td>26 (7.0)</td><td>19 (6.3)</td><td>7 (10.5)</td><td></td></tr><tr><td>Depression<sup>g</sup> (6.1)</td><td></td><td></td><td></td><td>&lt;0.001</td></tr><tr><td>No</td><td>305 (82.0)</td><td>266 (88.1)</td><td>39 (55.7)</td><td></td></tr><tr><td>Yes</td><td>67 (18.0)</td><td>36 (11.9)</td><td>31 (44.3)</td><td></td></tr><tr><td>Quality of life related to<br>social relationships<sup>h</sup> (3.0)</td><td>14 [12–16]</td><td>15 [13–7]</td><td>11 [9–13]</td><td>&lt;0.001</td></tr></tbody></table>

Abbreviations: HCV, hepatitis C virus; IQR, interquartile range.

<sup>a</sup>Chi-squared or Fisher exact test for categorical variables, and Kruskal-Wallis test for continuous variables.

<sup>b</sup>Answering ‘very much’ or ‘an extreme amount’ to the WHOQOL-HIV BREF item ‘To what extent do you feel that physical pain prevents you from doing what you need to do?’ [56].

<sup>c</sup>According to the laboratory test threshold.

<sup>d</sup>Seven substances or substance groups were considered, as follows: tobacco, cannabis, alcohol, stimulants, opioids, empathogens, and LSD or other hallucinogens. For each of them, a score of 0 or 1 was assigned to each participant according to criteria detailed in the text. The global substance use score is the sum of those scores.

<sup>e</sup>Unhealthy alcohol use is defined as an AUDIT-C score ≥3 for women and ≥4 for men [53].

<sup>f</sup>Any use of stimulants, opioids, empathogens, and LSD or other hallucinogens in the past 4 weeks.

<sup>g</sup>Depression was defined as either being prescribed an anti-depressant treatment or, for the 23 participants (5.8% of the study sample) with missing data on anti-depressant treatment prescription, having a PHQ-9 score ≥10.

<sup>h</sup>The social relationships dimension of quality of life was assessed through the corresponding WHOQOL-HIV BREF domain [56]. The associated score ranges from 4 to 20, with higher score values denoting better social relationships.

of life related to social relationships (0.72 [0.64–0.80]) were also significantly associated with SI.

DISCUSSION

Our findings confirm the hypothesis that in aging PWH cured of HCV, perceived disabling physical pain is strongly associated with suicidal ideation, even when accounting for other known predictors, including depression and substance use. They also confirm that lower

social relationship-related quality of life is independently associated with SI.

Associations between SI and depression, substance use, and low social support have previously been reported among PWH [13]. Overall quality of life has also been associated with SI in this population [13]. In a representative study of PWH receiving care in France, suicide risk has been found associated with reporting a feeling of loneliness [41], consistent with the results found in the present study, and suggesting the importance of social support interventions in preventing suicide [70].
<table><caption>TABLE 2 Association between perceived disabling physical pain and suicidal ideation in people living with HIV cured of hepatitis C (univariable and multivariable logistic regression, cross-sectional survey nested within the ANRS CO13 HEPAVIH cohort).</caption><thead><tr><th>Explanatory variables</th><th>Univariable analysis (N = 396)<br>OR [95% CI]</th><th>p-Value</th><th>Multivariable analysis (N = 376)<br>aOR [95% CI]</th><th>p-Value</th></tr></thead><tbody><tr><td>Perceived disabling physical pain<sup>a</sup></td><td></td><td></td><td></td><td></td></tr><tr><td>No (ref.)</td><td>1</td><td></td><td>1</td><td></td></tr><tr><td>Yes</td><td>3.75 [1.93-7.30]</td><td>&lt;0.001</td><td>3.07 [1.29-7.34]</td><td>0.012</td></tr><tr><td>Sex</td><td></td><td></td><td></td><td></td></tr><tr><td>Male (ref.)</td><td>1</td><td></td><td></td><td></td></tr><tr><td>Female</td><td>1.43 [0.82-2.50]</td><td>0.207</td><td></td><td></td></tr><tr><td>Age (in years)</td><td>0.98 [0.9-1.02]</td><td>0.303</td><td></td><td></td></tr><tr><td>Place of birth</td><td></td><td></td><td></td><td></td></tr><tr><td>France (ref.)</td><td>1</td><td></td><td></td><td></td></tr><tr><td>Abroad</td><td>0.75 [0.39-1.45]</td><td>0.390</td><td></td><td></td></tr><tr><td>Living in couple</td><td></td><td></td><td></td><td></td></tr><tr><td>No (ref.)</td><td>1</td><td></td><td></td><td></td></tr><tr><td>Yes</td><td>0.63 [0.37-1.08]</td><td>0.092</td><td></td><td></td></tr><tr><td>HIV transmission mode</td><td></td><td></td><td></td><td></td></tr><tr><td>Male-to-male sex</td><td>2.04 [0.60-6.94]</td><td>0.252</td><td></td><td></td></tr><tr><td>Heterosexual sex (ref.)</td><td>1</td><td></td><td></td><td></td></tr><tr><td>Injecting drug use</td><td>2.87 [1.09-7.55]</td><td>0.033</td><td></td><td></td></tr><tr><td>Other/unknown</td><td>1.76 [0.52-5.93]</td><td>0.364</td><td></td><td></td></tr><tr><td>HIV viral load<sup>b</sup></td><td></td><td></td><td></td><td></td></tr><tr><td>Undetectable (ref.)</td><td>1</td><td></td><td></td><td></td></tr><tr><td>Detectable</td><td>2.40 [1.14-5.04]</td><td>0.021</td><td></td><td></td></tr><tr><td>No lab results</td><td>1.57 [0.64-3.85]</td><td>0.321</td><td></td><td></td></tr><tr><td>Time since HIV diagnosis (in years)</td><td>0.99 [0.96-1.03]</td><td>0.672</td><td></td><td></td></tr><tr><td>Time since HCV diagnosis (in years)</td><td>1.01 [0.96-1.05]</td><td>0.779</td><td></td><td></td></tr><tr><td>CD4 cell count (in cells/mL)</td><td></td><td></td><td></td><td></td></tr><tr><td>&gt;500 (ref.)</td><td>1</td><td></td><td></td><td></td></tr><tr><td>351-500</td><td>2.17 [1.12-4.21]</td><td>0.022</td><td></td><td></td></tr><tr><td>200-350</td><td>1.21 [0.50-2.96]</td><td>0.672</td><td></td><td></td></tr><tr><td>&lt;200</td><td>1.24 [0.34-4.56]</td><td>0.747</td><td></td><td></td></tr><tr><td>No lab results</td><td>0.75 [0.27-2.02]</td><td>0.565</td><td></td><td></td></tr><tr><td>History of interferon treatment</td><td></td><td></td><td></td><td></td></tr><tr><td>No (ref.)</td><td>1</td><td></td><td></td><td></td></tr><tr><td>Yes</td><td>0.66 [0.38-1.16]</td><td>0.148</td><td></td><td></td></tr><tr><td>History of efavirenz treatment</td><td></td><td></td><td></td><td></td></tr><tr><td>No (ref.)</td><td>1</td><td></td><td></td><td></td></tr><tr><td>Yes</td><td>0.69 [0.40-1.18]</td><td>0.177</td><td></td><td></td></tr><tr><td>Number of psychoactive substances used<sup>c</sup></td><td></td><td></td><td></td><td></td></tr><tr><td>0 (ref.)</td><td>1</td><td></td><td>1</td><td></td></tr><tr><td>1</td><td>2.39 [1.14-5.02]</td><td>0.021</td><td>2.02 [0.79-5.18]</td><td>0.143</td></tr><tr><td>2</td><td>3.25 [1.55-6.87]</td><td>0.002</td><td>2.78 [1.07-7.26]</td><td>0.037</td></tr></tbody></table>

(Continues)
<table><caption>TABLE 2 (Continued)</caption><thead><tr><th rowspan="2">Explanatory variables</th><th>Univariable analysis (N = 396)</th><th rowspan="2">p-Value</th><th>Multivariable analysis (N = 376)</th><th rowspan="2">p-Value</th></tr><tr><th>OR [95% CI]</th><th>aOR [95% CI]</th></tr></thead><tbody><tr><td>≥3</td><td>3.81 [1.45–10.06]</td><td>0.007</td><td>5.42 [1.73–16.93]</td><td>0.004</td></tr><tr><td>Depression<sup>d</sup></td><td></td><td></td><td></td><td></td></tr><tr><td>No (ref.)</td><td>1</td><td></td><td>1</td><td></td></tr><tr><td>Yes</td><td>5.81 [3.26–10.36]</td><td>&lt;0.001</td><td>5.52 [2.66–11.43]</td><td>&lt;0.001</td></tr><tr><td>Quality of life related to social relationships<sup>e</sup></td><td>0.70 [0.64–0.80]</td><td>&lt;0.001</td><td>0.72 [0.64–0.80]</td><td>&lt;0.001</td></tr></tbody></table>

Note: Bold values in the “p-Value” column corresponds to the overall p-values for the explanatory variables having more than 2 categories.

Abbreviations: aOR, adjusted odds ratio; CI, confidence interval; OR, odds ratio.

ªAnswering ‘very much’ or ‘an extreme amount’ to the WHOQOL-HIV BREF item ‘To what extent do you feel that physical pain prevents you from doing what you need to do?’ [56].

ᵇAccording to the laboratory test threshold.

ᶜSeven substances or substance groups were considered, as follows: tobacco, cannabis, alcohol, stimulants, opioids, empathogens, and LSD or other hallucinogens. For each of them, a score of 0 or 1 was assigned to each participant according to criteria detailed in the text. The global substance use score is the sum of those scores.

ᵈDepression was defined as either being prescribed an anti-depressant treatment or, for the 23 participants (5.8% of the study sample) with missing data on anti-depressant treatment prescription, having a PHQ-9 score ≥10.

ᵉThe social relationships dimension of quality of life was assessed through the corresponding WHOQOL-HIV BREF domain [56]. The associated score ranges from 4 to 20, with higher score values denoting better social relationships.

However, to our knowledge, no previous study has specifically documented an independent association between physical pain and SI among PWH. Sherr et al. found such an association between physical burden score and SI in PWH in the UK [71]. The association between perceived disabling physical pain and SI we found aligns with findings reported in individuals experiencing physical pain [72], older adults [73], and in those with chronic pain in the general population [74, 75]. In the latter group, independent and concomitant effects of perceived pain and depression on suicide behaviours have been reported [76].

It should be noted that pain and depression are closely interrelated and may mutually exacerbate both physical and psychological symptoms [77]. Pain can also manifest as a symptom of depression in the absence of any nociceptive stimulus [78]. Therefore, we cannot exclude the possibility that our measure of pain partially captured depressive symptoms, and that part of the observed effect of pain may, in fact, be attributable to depression.

As previously reported [13], depression had the strongest association with SI among all variables examined in our study, underscoring the importance of depression screening and referral to care to reduce suicide risk among PWH. In our study population, the risk of SI was more than three times higher among participants reporting perceived disabling physical pain compared to those who did not. Those results highlight the potential clinical utility of brief pain screening [79], alongside depression and substance use in PWH, particularly among those with a history of chronic hepatitis C. Notably, substance

use may serve as a pain self-management strategy among PWH [80], and chronic pain in PWH is more prevalent in older individuals with complex medical, psychiatric, and substance use comorbidities [81]. Additionally, individuals with chronic opioid exposure, such as individuals with a history of injecting drug use (61.4% of our study population), may develop hyperalgesia, defined as an increased sensitivity and experience of pain [82, 83]. In a previous French cohort, PWH who had been infected via injecting drug use reported more painful anti-retroviral-related side effects than those who had been infected via other ways [84].

Consistent with previous studies, we observed an association between substance use—especially polysubstance use—and SI [18, 57, 85–88]. It has been shown that people with and without a history of substance use both experience great benefits from direct-acting antiviral treatments, in terms of mortality and liver-related events [89, 90]. However, even if decreases may be observed, substance use is likely to persist after HCV cure [52, 91, 92]. Therefore, integrated HCV treatment models that include addiction care [93–95] may, if effective in reducing substance use, lower the risk of SI among individuals previously infected with HCV.

The prevalence of SI was high (17.8%), in line with in the findings of Pei et al.'s meta-analysis among PWH (20.9%) [12]. These findings suggest that a history of HCV infection does not further increase the risk of SI in this population. This figure is, however, higher than the suicidality prevalence of 3.96% estimated in the European general population [96]. Although direct comparisons are difficult, our prevalence estimate also appears to lie
towards the upper end of the range reported in studies
focusing on aging populations [73, 97–100].

The main strength of our study lies in the simulta-
neous inclusion of data on depression, substance use,
physical pain, the social dimension of quality of life, and
clinical data in the analysis of factors associated with
SI. This approach enabled us to highlight the independent
contribution of perceived disabling physical pain on SI. SI
may arise from a great variety of conditions. While pain
seems to be a major driver of the relationship between
multi-morbidity and SI [101], the complexity of SI calls on
us not to overlook the possible influence of unmeasured
confounding factors, including comorbid conditions. Other
mental health conditions likely to impact SI, such as post-
traumatic stress disorder [102], as well as the use of non-
pharmacological therapies, such as psychotherapy, were
also not assessed. We used a single item to assess physical
pain. In return for its simplicity of implementation, such a
tool may have masked the role of diverse types of pain. It
may also be biased by inter-individual differences in per-
ceptions of pain, and by the diversity of daily needs that
may lead to different levels of reported disability for a
given level of pain. Further research is needed to identify
which types, location, and dimensions of physical pain
should be prioritized for management in PWH cured of
HCV. Similarly, substance use and receiving drug prescrip-
tions against depression were self-reported, and may have
been underreported. Lastly, we were limited by the cross-
sectional nature of data collection, which did not enable
us to assess how SI and associated factors evolve over time,
hindering the possibility of inferring any causal directions
in the associations we found.

In conclusion, these findings highlight that disabling
physical pain should be systematically addressed among
PWH cured of HCV, given its independent association with
SI. Routine HIV follow-up care should integrate systematic
screening for pain, mental health problems, and lack of
social support. Timely referral to specialized services may
help prevent future suicidal behaviours in this population.

AUTHOR CONTRIBUTIONS

PS, KO, TS, SA, SB-R contributed to the study concep-
tion, design, data acquisition and interpretation. CR per-
formed formal analysis. TB, CR, CP, PC and FM were
involved in study conception, methodology, interpreta-
tion and drafting of the manuscript. All authors reviewed
and approved the final version of the manuscript.

ACKNOWLEDGEMENTS

We thank all study participants.

The ANRS CO13 HEPAVIH Study Group:

*Scientific Committee of the ANRS CO13 HEPAVIH*
*Study Group:* D. Salmon (co-principal investigator),

L. Wittkop (co-principal investigator and methodologist),
P. Sogni (co-principal investigator), P. Carrieri, B. Spire,
K. Ory (project manager), P. Trimoulet, J. Izopet,
L. Serfaty, L. Alric, M. A. Valantin, G. Pialoux, J. Chas,
K. Barange, A. Naqvi, E. Rosenthal, A. Bicart-See,
O. Bouchaud, A. Gervais, C. Lascoux-Combe, C. Goujard,
K. Lacombe, C. Duvivier, D. Neau, P. Morlat, F. Bani-
Sadr, F. Boufassa, C. Solas, H. Fontaine, L. Piroth,
A. Simon, D. Zucman, F. Boué, P. Miailhes, E. Billaud,
H. Aumaître, D. Rey, G. Peytavin, O. Zaeglel-Faucher,
representative members of the sponsor (clinical research
and pharmacovigilance department, representative mem-
bers of patient organization including TRT5).

*Clinical Centres (ward/participating physicians)*: APHP, Hôpitaux Universitaires Paris Centre, Paris (Médecine Interne et Maladies Infectieuses: D. Salmon, R. Usubillaga; Hépato-gastro-entérologie: P. Sogni, B. Bienvenu, O. Launay-Puybasset, C. Bernasconi, A. Brunet, B. Silbermann, H. Boucher, F. Rollot, O. Zak Dit Zbar, S. Pol, C. Le Jeunne-Ballif, P. Louergue, H. Mehawej, L. Merine-Belardi, F. Almasi, N. Benammar, L. Alagna, S. Chaussade, L. Guillevin; Anatomo-pathologie: B. Terris; Virologie: C. Norgeux); APHP Pitié-Salpétrière, Paris (Maladies Infectieuses et Tropicales: C. Katlama, M. A. Valantin, H. Stitou, F. Caby, L. Paris, L. Schneider, R. Tubiana; Médecine Interne: A. Simon, L. Roudière, O. Benveniste, G. Breton, M. Bonmarchand, M. Kirstetter; Anatomo-pathologie: F. Charlotte, F. Capron; Virologie: V. Calvez, V. Thibaut, C. Soulie, B. Abdi, S. Lambert-Niclot); APHM Sainte-Marguerite, Marseille (Immuno-Hématologie Clinique: S. Bregigeon-Ronot, O. Zaegel-Faucher, H. Laroche, A. Menard, E. Gaubert-Marechal; Virologie: S. Thirée, C. Tamalet, C. Hakimi; Anatomo-pathologie: J. C. Poluzzi; Pharmacologie: C. Solas); APHP Tenon, Paris (Maladies Infectieuses et Tropicales: G. Pialoux, J. Chas, L. Lassel, T. Lyavanc, S. Le Nagat, L. Slama, A. Canesti; Anatomo-pathologie: P. Callard; Virologie: B. Bachour); CHU Purpan, Toulouse (Médecine interne: L. Alric, N. Sigur, D. Bonnet, M. Guivarch; Hépato-gastro-entérologie: K. Barange, J. M. Peron, P. Massip, L. Cuzin, M. Obada, E. Bonnet, M. Alvarez, E. Labau, M. Mularczyk, N. Bourdoncle, J. Penecy, L. Porte, F. Busato, S. Khatibi, J. Bernard; Anatomo-pathologie: J. Selves; Virologie: F. Larroquette, V. Ferrer, J. Chiabrandon); CHU Archet, Nice (Médecine Interne: E. Rosenthal, C. Pradier, V. Mondain, P. Dellamonica, P. M. Roger, S. Ferrando, C. Ceppi; Infectiologie: A. Naqvi, V. Rio, B. Dunais, B. Prouvost, F. De Salvadore-Guillouet, I. Prebost, J. Durant, P. Pugliese; Anatomo-pathologie: J. F. Michels, M. C. Saint-Paul; Virologie: C. Partouche, K. Nerini); APHP Avicenne, Bobigny (Médecine Interne, Unité VIH: O. Bouchaud, S. Abgrall, I. Zamord, F. Bidegain,
M. Azghay, C. Rouyer, M. Tatay, F. Mechai; Anatomopathologie: A. Martin; Virologie: Y. Baazia, V. Iwakabande, A. Gerber); Hôpital Joseph Ducuing, Toulouse (Médecine Interne: A. Bicart-See, D. Garipuy, M. J. Ferro-Collados, F. Gaches; Virologie: F. Abravanel, F. Larroquette, J. Chiabrandon); APHP Bichat—Claude-Bernard, Paris (Maladies Infectieuses: A. Gervais, Y. Yazdanpanah; Anatomopathologie: D. Henin; Virologie: M. Bertine, M. Onambele; Pharmacologie: G. Peytavin); APHP Saint-Louis, Paris (Maladies infectieuses: C. Lascoux-Combe, T. Kandel, C. Pintado, J. M. Molina, C. Gatey, S. Gallien, W. Rozenbaum, M. Lafaurie, A. L. Munier, D. Ponscarme, M. Previllon, N. Colin De Verdière, M. G. Tateo; Virologie: P. Palmer, A. Gabassi, R. Amarsy, M. C. Mazeron); APHP Saint-Antoine (Maladies Infectieuses et Tropicales: K. Lacombe, J. Krause, P. Ingiliz, P. M. Girard, B. Lefebvre, N. Valin, M. C. Mehoyas, S. Fournier, J. L. Meynard, Z. Ouazene, H. Guyon, P. Roussard, F. Lallemand, G. Raguin, D. Bollens, M. Tourneur, H. Bideault, L. Fonquernie, J. Pacanowski; Anatomopathologie: D. Wendum; Virologie: D. Fofana, T. Thithuthuon); APHP, Hôpitaux Paris Sud, Bicêtre/Paul Brousse (Médecine Interne: C. Goujard, Y. Quertainmont, E. Teicher, L. Escaut, O. Derradji; Virologie: C. Pallier, F. Veillet, L. Mouna); APHP Necker, Paris (Maladies Infectieuses et Tropicales: O. Lortholary, C. Duvivier, C. Rouzaud, M. Shoai Tehrani, S. Bouly, G. Obenga, J. P. Viard; Virologie: E. Gardiennet, A. Mélard); CHU Bordeaux Hôpital Pellegrin, Bordeaux (Maladies Infectieuses et Tropicales: D. Neau, A. Ochoa, E. Blanchard, C. Cazanave, M. Dupon, H. Dutronc, F. Dauchy, H. Wille; Anatomopathologie: P. Bioulac-Sage; Virologie: P. Trimoulet); CHU Bordeaux Hôpital Saint-André, Bordeaux (Médecine Interne et Maladies Infectieuses: P. Morlat, D. Lacoste, F. Bonnet, N. Bernard, M. Hessamfar, F. Paccalin, C. Martell, M. C. Pertusa, M. Vandenhende, P. Mercié, T. Pistone, M. C. Receveur, M. Méchain, P. Duffau, C. Rivoisy, I. Faure, D. Malvy, J. Roger-Schmeltz, D. Dondia; Anatomopathologie: P. Bioulac-Sage; Virologie: P. Trimoulet); CHU Bordeaux Hôpital Haut-Levéque, Bordeaux (Médecine Interne: J. L. Pellegrin, E. Lazzaro; Anatomopathologie: P. Bioulac-Sage; Virologie: P. Trimoulet); Hôpital Foch, Suresnes (Médecine Interne: D. Zucman, C. Majerholc, J. E. Kahn, S. Hilaire; Virologie: M. Brollo); APHP Antoine Béclère, Clamart (Médecine Interne: F. Boué, S. Abgrall, J. Polo Devoto, I. Kansau, V. Chambrin, C. Pignon, C. Gatey, M. Favier; Virologie: C. Deback, C. Vauloup, C. Pailler, F. Veillet, L. Mouna); CHU Henri Mondor, Créteil (Immunologie Clinique: J. L. Lopez Zaragoza, Y. Lévy, J. D. Lelièvre, A. S. Lascaux, S. Scerra; Virologie: M. Bouvier-Alias); CHU Nantes Hôpital Hôtel Dieu, Nantes (Maladies Infectieuses et Tropicales: E. Billaud,

F. Raffi, C. Allavena, V. Reliquet, D. Boutoille, C. Biron, M. Lefebvre, N. Hall, S. Bouchez, C. Bernaud, O. Mounoury; Virologie: A. Rodallec, L. Le Guen); Hôpital de la Croix Rousse, Lyon (Maladies Infectieuses et Tropicales: P. Miailhes, D. Peyramond, C. Chidiac, F. Ader, F. Biron, A. Boibieux, L. Cotte, T. Ferry, T. Perpoint, M. Amiri, F. Valour; Hépato-gastro-entérologie: J. Koffi, F. Zoulim, F. Bailly, P. Lack, M. Maynard, S. Radenne, C. Augustin-Normand; Virologie: E. Vassel, T. T. Le-Thi); CHU Dijon, Dijon (Infectiologie: L. Piroth, P. Chavanet, M. Duong Van Huyen, M. Buisson, A. Waldner-Combernoux, S. Mahy, A. Fillion); CH Perpignan, Perpignan (Maladies infectieuses et tropicales: H. Aumaitre, M. Jean, A. Eden, M. Medus, M. Saada; Virologie: S. Gaba); CHU Robert Debré, Reims (Médecine interne, maladies infectieuses et immunologie clinique: F. Bani-Sadr, D. Lambert, Y. Nguyen, J. L. Berger, C. Rouger; Virologie: V. Brodard); CHRU Strasbourg (Le Trait d'Union: D Rey, M. Partasani, C. Cheneau, M. Priester, C. Bernard-Henry, E. de Mautort; Virologie: A. Ertle, F. Jegou, A. Fush, P. Gantner, S. Fafi-Kremer).

*Data collection:* L. Pinheiro, F. Roustand*, I. Kmiec, L. Traore*, S. Le Puil*, M. G. Tateo*, S. Benothame*, C. Pomes*, C. Louisin, M. Mole*, A. Adda, P. Thibaut, S. Poirier, R. Ben Rayana*, M. P. Pietri, V. Le Baut, Y. Cuvillier, M. Alabatanah*, F. Barret, F. Juster, C. Chesnel*, D. Beniken, M. Sebire-Le Cam, R. Monard, F. Badji*, S. Caldato, T. Rojas Rojas, A. S. Ritleng, A. Ivanova, L. Chalal, Z. Julia, M. Cavellec, C. Chevalier, E. Paredes-Manyari, S. Breau, N. Boughdiri, P. Fischer, C. Charles, S. Ogoudjobi, C. Brochier, V. Thoirain-Galvan, L. Traore, S. Chaussee, S. Benothmane, A. Sondro, O. Camou, V. Godard, M. Kai.

*Management, statistical analyses:* C. Gilbert, M. Pailler, L. Merchadou, L. Esterle*, K. Ory, S. Gillet-Rousseau, C. Khan*, L. Abbad, M. Chalouni*, V. Conte, F. Marcellin, R. Knight, M. Mora, C. Protopopescu, P. Roux, T. Barré.

*People who are no longer active but who participated in the cohort.

## FUNDING INFORMATION

This work was supported by the ANRS Emerging Infectious Diseases, with the participation of SIDACTION, Abbott France, Glaxo-Smith-Kline, Roche, Schering-Plough, BMS, and Merck-Serono.

## CONFLICT OF INTEREST STATEMENT

The authors declare no conflicts of interest.

## DATA AVAILABILITY STATEMENT

The data that support the findings of this study are available on request from the corresponding author.
The data are not publicly available due to privacy or ethical restrictions.

## ETHICS STATEMENT

The ANRS CO13 HEPAVIH cohort was designed and implemented in accordance with the Declaration of Helsinki and was approved by the ethics committee of the Cochin University Hospital in Paris.

## PATIENT CONSENT STATEMENT

Written informed consent was collected for all participants.

## ORCID

Tangui Barré https://orcid.org/0000-0002-3439-8868

Clémence Ramier https://orcid.org/0000-0002-1928-0263

Camelia Protopopescu https://orcid.org/0000-0003-0164-7917

Philippe Sogni https://orcid.org/0000-0003-3316-8785

Sophie Abgrall https://orcid.org/0000-0002-7891-7594

Sylvie Brégigeon-Ronot https://orcid.org/0000-0002-2735-7793

Patrizia Carrieri https://orcid.org/0000-0002-6794-4837

Fabienne Marcellin https://orcid.org/0000-0001-8853-3829

## REFERENCES

1. Hoare J, Sevenoaks T, Mtukushe B, Williams T, Heany S, Phillips N. Global systematic review of common mental health disorders in adults living with HIV. *Curr HIV/AIDS Rep.* 2021;18:569-580.

2. Hu F-H, Liu P, Jia Y-J, et al. Prevalence of mental health problems in people living with HIV: a systematic review and meta-analysis. *Psychol Health Med.* 2025;30:397-413.

3. Duko B, Ayalew M, Ayano G. The prevalence of alcohol use disorders among people living with HIV/AIDS: a systematic review and meta-analysis. *Subst Abuse Treat Prev Policy.* 2019; 14:52.

4. Hartzler B, Dombrowski JC, Crane HM, et al. Prevalence and predictors of substance use disorders among HIV care enrollees in the United States. *AIDS Behav.* 2017;21:1138-1148.

5. Lesko CR, Falade-Nwulia OO, Pytell JD, et al. Joint effects of substance use disorders and recent substance use on HIV viral non-suppression among people engaged in HIV care in an urban clinic, 2014-2019. *Addiction.* 2023;118:2193-2202.

6. Lier AJ, Tarfa A, Shenoi SV, Kuo I, Springer SA. HIV and substance use disorders. *Infect Dis Clin North Am.* 2024;38: 599-611.

7. Vollmond CV, Tetens MM, Paulsen FW, et al. Risk of depression in people with human immunodeficiency virus: a Nationwide population-based matched cohort study. *Clin Infect Dis.* 2023;77:1569-1577.

8. Ahmed GY, Saha C, Almusalami EM, et al. Prevalence of depression in elderly people living with HIV: a systematic review and meta-analysis. *Infect Microbes Dis.* 2023;5:167-171.

9. Havlik RJ, Brennan M, Karpiak SE. Comorbidities and depression in older adults with HIV. *Sex Health.* 2011;8: 551-559.

10. Rafiei S, Raoofi S, Pashazadeh Kan F, et al. Global prevalence of suicide in patients living with HIV/AIDS: a systematic review and meta-analysis. *J Affect Disord.* 2023;323:400-408.

11. Pelton M, Ciarletta M, Wisnousky H, et al. Rates and risk factors for suicidal ideation, suicide attempts and suicide deaths in persons with HIV: a systematic review and meta-analysis. *Gen Psych.* 2021;34:e100247.

12. Pei J-H, Pei Y, Ma T, et al. Prevalence of suicidal ideation, suicide attempt, and suicide plan among HIV/AIDS: a systematic review and meta-analysis. *J Affect Disord.* 2021;292:295-304.

13. Tsai Y-T, Padmalatha S, Ku H-C, et al. Suicidality among people living with HIV from 2010 to 2021: a systematic review and a meta-regression. *Psychosom Med.* 2022;84:924-939.

14. Armoon B, Fleury M-J, Bayani A, Mohammadi R, Ahounbar E, Griffiths MD. Suicidal behaviors among intravenous drug users: a meta-analysis. *J Subst Abuse.* 2024;29:10-20.

15. Nouri E, Moradi Y, Moradi G. The global prevalence of suicidal ideation and suicide attempts among men who have sex with men: a systematic review and meta-analysis. *Eur J Med Res.* 2023;28:361.

16. Yu Y, Luo B, Qin L, Gong H, Chen Y. Suicidal ideation of people living with HIV and its relations to depression, anxiety and social support. *BMC Psychol.* 2023;11:159.

17. Ogundipe OA, Olagunju AT, Adeyemi JD. Suicidal ideation among attendees of a west African HIV clinic. *Arch Suicide Res.* 2015;19:103-116.

18. Gizachew KD, Chekol YA, Basha EA, Mamuye SA, Wubetu AD. Suicidal ideation and attempt among people living with HIV/AIDS in selected public hospitals: Central Ethiopia. *Ann Gen Psychiatry.* 2021;20:15.

19. Bitew H, Andargie G, Tadesse A, Belete A, Fekadu W, Mekonen T. Suicidal ideation, attempt, and determining factors among HIV/AIDS patients, Ethiopia. *Depress Res Treat.* 2016;2016:8913160.

20. Tamirat KS, Tesema GA, Tessema ZT. Psychosocial factors associated with suicidal ideation among HIV/AIDS patients on follow-up at Dessie referral hospital, Northeast Ethiopia: a cross-sectional study. *HIV/AIDS.* 2021;13:415-423.

21. Wang W, Xiao C, Yao X, Yang Y, Yan H, Li S. Psychosocial health and suicidal ideation among people living with HIV-/AIDS: a cross-sectional study in Nanjing, China. *PLoS One.* 2018;13:e0192940.

22. Amiya RM, Poudel KC, Poudel-Tandukar K, Pandey BD, Jimba M. Perceived family support, depression, and suicidal ideation among people living with HIV/AIDS: a cross-sectional study in the Kathmandu Valley, Nepal. *PLoS One.* 2014;9:e090959.

23. Bogale EK, Zewdie A, Kassie TD, et al. Suicidal ideation, attempt, and its associated factors among adult HIV/AIDS patients in Ethiopia: a systematic review and meta-analysis study. *PLoS One.* 2024;19:e0294078.

24. Fu J, Chen X, Dai Z, et al. HIV-related stigma, depression and suicidal ideation among HIV-positive MSM in China: a moderated mediation model. *BMC Public Health.* 2023;23:2117.

25. Arashiro P, Maciel CG, Freitas FPR, et al. Adherence to anti-retroviral therapy in people living with HIV with moderate or severe mental disorder. *Sci Rep.* 2023;13:3569.
26. Rukundo GZ, Levin J, Mpango RS, Patel V, Kinyanda E. Effect of suicidality on clinical and behavioural outcomes in HIV positive adults in Uganda. *PLoS One*. 2021;16:e0254830.

27. Parker R, Stein DJ, Jelsma J. Pain in people living with HIV-/AIDS: a systematic review. *J Int AIDS Soc*. 2014;17:18719.

28. Kowalski M, Horban A, Slomka B, Shahnazaryan K, Rongies W. Is age and not antiretroviral therapy the strongest risk factor for chronic pain in HIV-infected population? *BMC Infect Dis*. 2021;21:136.

29. Madden VJ, Parker R, Goodin BR. Chronic pain in people with HIV: a common comorbidity and threat to quality of life. *Pain Manag*. 2020;10:253-260.

30. Bristowe K, Clift P, James R, et al. Towards person-centred care for people living with HIV: what core outcomes matter, and how might we assess them? A cross-national multi-centre qualitative study with key stakeholders. *HIV Med*. 2019;20:542-554.

31. Denis CM, Morales KH, Wu Q, Metzger DS, Cheatle MD. Association between diagnoses of chronic noncancer pain, substance use disorder, and HIV-related outcomes in people living with HIV. *J Acquir Immune Defic Syndr*. 2019;82:S142-S147.

32. Scott W, Arkuter C, Kioskli K, et al. Psychosocial factors associated with persistent pain in people with HIV: a systematic review with meta-analysis. *Pain*. 2018;159:2461-2476.

33. Rukundo GZ, Kinyanda E, Mishara B. Clinical correlates of suicidality among individuals with HIV infection and AIDS disease in Mbarara, Uganda. *Afr J AIDS Res*. 2016;15:227-232.

34. Dafoe ME, Stewart KE. Pain and psychiatric disorders contribute independently to suicidal ideation in HIV-positive persons. *Arch Suicide Res*. 2004;8:215-226.

35. Uebelacker LA, Weisberg RB, Herman DS, Bailey GL, Pinkston MM, Stein MD. Chronic pain in HIV-infected patients: relationship to depression, substance use, and mental health and pain treatment. *Pain Med*. 2015;16:1870-1881.

36. Tsao JCI, Soto T. Pain in persons living with HIV and comorbid psychological and substance use disorders. *Clin J Pain*. 2009;25:307-312.

37. Merlin JS, Westfall AO, Raper JL, et al. Pain, mood, and substance abuse in HIV: implications for clinic visit utilization, ART adherence, and virologic failure. *J Acquir Immune Defic Syndr*. 2012;61:164-170.

38. Yeoh SW, Holmes ACN, Saling MM, Everall IP, Nicoll AJ. Depression, fatigue and neurocognitive deficits in chronic hepatitis C. *Hepatol Int*. 2018;12:294-304.

39. Trickey A, Fraser H, Lim AG, et al. The contribution of injection drug use to hepatitis C virus transmission globally, regionally, and at country level: a modelling study. *Lancet Gastroenterol Hepatol*. 2019;4:435-444.

40. Clark PJ, Valery PC, Strasser SI, et al. Alcohol does not impact chronic hepatitis C treatment outcomes but increases risk for progressive liver disease: findings from a prospective multi-centre Australian study (OPERA-C). *Drug Alcohol Rev*. 2024; 43:1559-1572.

41. Carrieri MP, Marcellin F, Fressard L, et al. Suicide risk in a representative sample of people receiving HIV care: time to target most-at-risk populations (ANRS VESPA2 French national survey). *PLoS One*. 2017;12:e0171645.

42. Abdel Moez AT, El Hawary YA, Al Balakosy AM. Can successful treatment by direct-acting antivirals improve

depression in chronic HCV patients? *Eur J Gastroenterol Hepatol*. 2021;33:727-730.

43. Pericot-Valverde I, Lopes SS, Nahvi S, et al. Reduction in depressive symptoms in people who inject drugs who are cured of hepatitis C virus infection: the HERO study. *Open Forum Infect Dis*. 2023;10:ofad498.

44. Marathe G, Moodie EEM, Brouillette M-J, et al. Impact of hepatitis C virus cure on depressive symptoms in the human immunodeficiency virus-hepatitis C virus coinfected population in Canada. *Clin Infect Dis*. 2023;76:e702-e709.

45. Bertino G, Ragusa R, Corsaro LS, et al. Improvement of health-related quality of life and psychological well-being after HCV eradication with direct-acting antiviral agents. Real life setting data of an Italian cohort valued by hepatitis quality of life questionnaire (HQLQv2). *Health Psychol Res*. 2020;8:9450.

46. Kim HP, Edwards A, Reeve BB, Golin CE, Evon DM. Symptoms and functioning improve after chronic hepatitis C cure as assessed by the memorial symptom assessment scale and PROMIS measures. *J Viral Hepat*. 2021;28:1491-1495.

47. Yi C-H, Bair M-J, Wang J-H, et al. Improvement of patient-reported outcomes in patients achieving sustained virologic response with direct-acting antivirals for hepatitis C virus infection. *J Microbiol Immunol Infect*. 2022;55:643-650.

48. Tsui JI, Ludwig-Barron NT, James JR, et al. Current self-reported pain before and after cure of hepatitis C among persons who actively inject drugs. *J Addict Med*. 2024;19:248-253.

49. Kumthekar A, Shull S, Lovejoy TI, Morasco BJ, Chang M, Barton J. Impact of hepatitis C treatment on pain intensity, prescription opioid use and arthritis. *Int J Rheum Dis*. 2019;22:592-598.

50. Marcellin F, Brégigeon-Ronot S, Ramier C, et al. Depressive symptoms after hepatitis C cure and socio-behavioral correlates in aging people living with HIV (ANRS CO13 HEPAVIH). *JHEP Rep*. 2023;5:100614.

51. Zanone MM, Marinucci C, Ciancio A, et al. Peripheral neuropathy after viral eradication with direct-acting antivirals in chronic HCV hepatitis: a prospective study. *Liver Int*. 2021;41:2611-2621.

52. Barré T, Mercié P, Lions C, et al. HCV cure: an appropriate moment to reduce cannabis use in people living with HIV? (ANRS CO13 HEPAVIH data). *AIDS Res Ther*. 2022;19:15.

53. Bush K, Kivlahan DR, McDonell MB, Fihn SD, Bradley KA. The AUDIT alcohol consumption questions (AUDIT-C): an effective brief screening test for problem drinking. Ambulatory Care Quality Improvement Project (ACQUIP). Alcohol Use Disorders Identification Test. *Arch Intern Med*. 1998;158:1789-1795.

54. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. *J Gen Intern Med*. 2001;16:606-613.

55. Edwards M, Quinlivan EB, Bess K, et al. Implementation of PHQ-9 depression screening for HIV-infected patients in a real-world setting. *J Assoc Nurses AIDS Care*. 2014;25:243-252.

56. O'Connell KA, Skevington SM. An international quality of life instrument to assess wellbeing in adults who are HIV-positive: a short form of the WHOQOL-HIV (31 items). *AIDS Behav*. 2012;16:452-460.

57. Satre DD, Sarovar V, Levine T, et al. Factors associated with suicidal ideation among people with HIV engaged in care. *J Affect Disord*. 2024;358:369-376.
58. Rossom RC, Coleman KJ, Ahmedani BK, et al. Suicidal ideation reported on the PHQ9 and risk of suicidal behavior across age groups. *J Affect Disord*. 2017;215:77-84.

59. Institut National de la Statistique et des Etudes Economiques. Niveau de vie et pauvreté des immigrés – Les revenus et le patrimoine des ménages / Standard of living and poverty among immigrants – Household income and wealth. INSEE EDITIONS; 2024.

60. Moullan Y, Jusot F. Why is the “healthy immigrant effect” different between European countries? *Eur J Public Health*. 2014;24(Suppl 1):80-86.

61. Abgrall S, Raho-Moussa M, Seng R, et al. Elevated risk of viral rebound on ART in migrants living in France: role of socioeconomic factors. *Antivir Ther*. 2019;24:541-552.

62. Barré T, Nishimwe ML, Protopopescu C, et al. Cannabis use is associated with a lower risk of diabetes in chronic hepatitis C-infected patients (ANRS CO22 Hepather cohort). *J Viral Hepat*. 2020;27:1473-1483.

63. James PB, Renzaho AMN, Mwanri L, et al. The prevalence of anxiety, depression, and post-traumatic stress disorder among African migrants: a systematic review and meta-analysis. *Psychiatry Res*. 2022;317:114899.

64. Yaya I, Amboise Y, Roucoux G, et al. Correlates of mental health of people living with HIV co-infected with SARS-CoV-2: findings from the COVIDHIV study in France. *Front Psychiatry*. 2025;15. doi:10.3389/fpsyt.2024.1437362/full

65. Mathian B, Menezes RG, Asim M, et al. Cigarette smoking dose-response and suicidal ideation among young people in Nepal: a cross-sectional study. *Nepal J Epidemiol*. 2020;10:821-829.

66. Shamabadi A, Ahmadzade A, Pirahesh K, Hasanzadeh A, Asadigandomani H. Suicidality risk after using cannabis and cannabinoids: an umbrella review. *Dialogues Clin Neurosci*. 2023;25:50-63.

67. Lange S, Llamosas-Falcón L, Kim KV, et al. A dose-response meta-analysis on the relationship between average amount of alcohol consumed and death by suicide. *Drug Alcohol Depend*. 2024;260:111348.

68. Hosmer DW, Lemeshow S. Applied Logistic Regression. Second ed. John Wiley & Sons, Inc; 2000. doi:10.1002/0471722146

69. Dunkler D, Plischke M, Leffondré K, Heinze G. Augmented backward elimination: a pragmatic and purposeful way to develop statistical models. *PLoS One*. 2014;9:e113677.

70. Hou X, Wang J, Guo J, et al. Methods and efficacy of social support interventions in preventing suicide: a systematic review and meta-analysis. *Evid Based Ment Health*. 2022;25:29-35.

71. Sherr L, Lampe F, Fisher M, et al. Suicidal ideation in UK HIV clinic attenders. *AIDS*. 2008;22:1651-1658.

72. Calati R, Laglaoui Bakhiyi C, Artero S, Ilgen M, Courtet P. The impact of physical pain on suicidal thoughts and behaviors: meta-analyses. *J Psychiatr Res*. 2015;71:16-32.

73. Almeida OP, Draper B, Snowdon J, et al. Factors associated with suicidal thoughts in a large community study of older adults. *Br J Psychiatry*. 2012;201:466-472.

74. Chincholkar M, Blackshaw S. Suicidality in chronic pain: assessment and management. *BJA Educ*. 2023;23:320-326.

75. Fishbain DA, Lewis JE, Gao J. The pain suicidality association: a narrative review. *Pain Med*. 2014;15:1835-1849.

76. Cheatle MD, Giordano NA, Themelis K, Tang NKY. Suicidal thoughts and behaviors in patients with chronic pain, with and without co-occurring opioid use disorder. *Pain Med*. 2023;24:941-948.

77. IsHak WW, Wen RY, Naghdechi L, et al. Pain and depression: a systematic review. *Harv Rev Psychiatry*. 2018;26:352-363.

78. Agüera-Ortiz L, Failde I, Mico JA, Cervilla J, López-Ibor JJ. Pain as a symptom of depression: prevalence and clinical correlates in patients attending psychiatric clinics. *J Affect Disord*. 2011;130:106-112.

79. Merlin JS, Walcott MM, Herbey I, et al. Qualitative investigation of a brief chronic pain screening tool in HIV-infected patients. *AIDS Patient Care STDS*. 2014;28:176-182.

80. Merlin JS, Walcott M, Kerns R, Bair MJ, Burgio KL, Turan JM. Pain self-management in HIV-infected individuals with chronic pain: a qualitative study. *Pain Med*. 2015;16:706-714.

81. Slawek DE. People living with HIV and the emerging field of chronic pain—what is known about epidemiology, etiology, and management. *Curr HIV/AIDS Rep*. 2021;18:436-442.

82. Compton P, Canamar CP, Hillhouse M, Ling W. Hyperalgesia in heroin dependent patients and the effects of opioid substitution therapy. *J Pain*. 2012;13:401-409.

83. Alford DP, Compton P, Samet JH. Acute pain management for patients receiving maintenance methadone or buprenorphine therapy. *Ann Intern Med*. 2006;144:127-134.

84. Carrieri MP, Villes V, Raffi F, et al. Self-reported side-effects of anti-retroviral treatment among IDUs: a 7-year longitudinal study (APROCO-COPILOTE COHORT ANRS CO-8). *Int J Drug Policy*. 2007;18:288-295.

85. Mandell LN, Rodriguez VJ, De La Rosa A, et al. Suicidal ideation among adults Re-engaging in HIV Care in Argentina. *AIDS Behav*. 2019;23:3427-3434.

86. Brown LA, Majeed I, Mu W, et al. Suicide risk among persons living with HIV. *AIDS Care*. 2021;33:616-622.

87. Uwiringiyimana A, Niyonsenga J, Lisette KG, Bugenimana A, Mutabaruka J, Nshimiyimana A. Depression symptoms and suicidal ideation among HIV infected Rwandans: the mediating and moderating effects of complicated grief and substance abuse. *AIDS Res Ther*. 2024;21:38.

88. Durham MD, Armon C, Mahnken JD, et al. Rates of suicidal ideation among HIV-infected patients in care in the HIV outpatient study 2000-2017, USA. *Prev Med*. 2020;134:106011.

89. Barré T, Bourlière M, Parlati L, et al. Hepatitis C virus cure from direct-acting antivirals and mortality: are people with and without a history of injection drug use in the same boat? (ANRS CO22 Hepather cohort). *Drug Alcohol Rev*. 2023;43:718-731.

90. Park H, Jiang X, Song HJ, et al. The impact of direct-acting antiviral therapy on end-stage liver disease among individuals with chronic hepatitis C and substance use disorders. *Hepatology*. 2021;74:566-581.

91. Tsui JI, Lum PJ, Taylor LE, et al. Injecting practices during and after hepatitis C treatment and associations with not
achieving cure among persons who inject drugs. *Drug Alcohol Depend*. 2023;247:109878.

92. Knight R, Roux P, Vilotitch A, et al. Significant reductions in alcohol use after hepatitis C treatment: results from the French ANRS CO13-HEPAVIH cohort: significant reductions in alcohol use. *Addiction*. 2017;112:1669-1679.

93. Proeschold-Bell RJ, Patkar AA, Maggie S, et al. An integrated alcohol abuse and medical treatment model for patients with hepatitis C. *Dig Dis Sci*. 2012;57:1083-1109.

94. Proeschold-Bell RJ, Evon DM, Yao J, et al. A randomized controlled trial of an integrated alcohol reduction intervention in patients with hepatitis C infection. *Hepatology*. 2020;71:1894-1909.

95. Ngo BV, James JR, Blalock KL, Jackson SL, Chew LD, Tsui JI. Hepatitis C treatment outcomes among patients treated in co-located primary care and addiction treatment settings. *J Subst Abuse Treat*. 2021;131:108438.

96. Castillejos MC, Huertas P, Martín P, Moreno Küstner B. Prevalence of suicidality in the European general population: a systematic review and meta-analysis. *Arch Suicide Res*. 2021; 25:810-828.

97. Corna LM, Cairney J, Streiner DL. Suicide ideation in older adults: relationship to mental health problems and service use. *Gerontologist*. 2010;50:785-797.

98. Zhu X-M, Xu Y-M, Wang Z-Q, Zhong B-L. Prevalence and correlates of suicidal ideation among older adults attending primary care clinics in Wuhan, China: a multi-center cross-sectional study. *Front Psychiatry*. 2022;13: 1003810.

99. Cabello M, Rico-Uribe LA, Martinez-Ávila JC, et al. The role of ageing in the wish to be dead: disentangling age, period and cohort effects in suicide ideation in European population. *Epidemiol Psychiatr Sci*. 2021;30:e17.

100. Stolz E, Fux B, Mayerl H, Rásky É, Freidl W. Passive suicide ideation among older adults in Europe: a multilevel regression analysis of individual and societal determinants in 12 countries (SHARE). *J Gerontol B Psychol Sci Soc Sci*. 2016;71:947-958.

101. Smith L, Shin JI, Lee S, et al. The association of physical multimorbidity with suicidal ideation and suicide attempts in England: a mediation analysis of influential factors. *Int J Soc Psychiatry*. 2023;69:523-531.

102. Mi T, Zhang J, Yang X, et al. Suicide ideation and attempt among people with HIV: a statewide population-level cohort analysis between 2005 and 2020. *J Acquir Immune Defic Syndr*. 2024;95:117-125.

**How to cite this article:** Barré T, Ramier C, Protopopescu C, et al. Perceived disabling physical pain and suicidal ideation in aging people living with HIV cured of hepatitis C: A multi-center survey in France (ANRS CO13 HEPAVIH). *HIV Med*. 2025;1-14. doi:10.1111/hiv.70121